Close
What would you like to look for?

29 January 2021

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, has signed a binding term sheet to acquire all shares in AdVita Lifescience GmbH ("AdVita"), a Germany-based, privately held pharmaceutical company de-veloping effective products and strategies to improve the treatment and diagnosis of rare lung diseases, in exchange for EUR 25m of Relief common shares, plus possible future contingent milestone payments of up to EUR 20m. The closing of the transaction is subject to customary closing conditions as well as legal and securities regulatory approvals and is expected to occur in Q2 2021.

VISCHER advises Relief as lead counsel and regarding the Swiss legal aspects of this transaction whereas K&L Gates acts as German counsel and Sterne Kessler as US IP counsel. The VISCHER team led by partner Dr. Robert Bernet (Corporate/M&A) comprises Dr. Peter Kühn (Counsel, Corporate/M&A), Florian Kambor (Junior Associate, Corporate/M&A) and Christian Wyss (Partner, IP).

Press release

Categories: Mergers & Acquisitions, Deals & Cases

Authors